Discounted Cash Flow (DCF) Analysis Levered

Globus Medical, Inc. (GMED)

$71.54

+0.40 (+0.56%)
All numbers are in Millions, Currency in USD

Free Cash Flow

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 635.98712.97785.37789.04958.101,063.861,181.301,311.701,456.491,617.27
Revenue (%)
Operating Cash Flow 159.54181.64171.97198.79276.27269.13298.84331.83368.46409.13
Operating Cash Flow (%)
Capital Expenditure -51.30-59.70-70.75-63.66-56.90-83.95-93.22-103.51-114.93-127.62
Capital Expenditure (%)
Free Cash Flow 108.23121.95101.22135.14219.38185.19205.63228.33253.53281.52

Weighted Average Cost Of Capital

Share price $ 71.54
Beta 1.055
Diluted Shares Outstanding 103.62
Cost of Debt
Tax Rate 17.30
After-tax Cost of Debt 4.13%
Risk-Free Rate
Market Risk Premium
Cost of Equity 8.671
Total Debt -
Total Equity 7,413.19
Total Capital -
Debt Weighting -
Equity Weighting -
Wacc

Build Up Free Cash Flow

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 635.98712.97785.37789.04958.101,063.861,181.301,311.701,456.491,617.27
Operating Cash Flow 159.54181.64171.97198.79276.27269.13298.84331.83368.46409.13
Capital Expenditure -51.30-59.70-70.75-63.66-56.90-83.95-93.22-103.51-114.93-127.62
Free Cash Flow 108.23121.95101.22135.14219.38185.19205.63228.33253.53281.52
WACC
PV LFCF -----
SUM PV LFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) -
Free cash flow (t + 1) 287.15
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -193.07
Equity Value -
Shares Outstanding 103.62
Equity Value Per Share -